273 related articles for article (PubMed ID: 34549809)
1. Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Jemielita T; Widman L; Fox C; Salomonsson S; Liaw KL; Pettersson A
Clin Pharmacol Ther; 2021 Dec; 110(6):1613-1621. PubMed ID: 34549809
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
3. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
[TBL] [Abstract][Full Text] [Related]
5. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.
Chen WC; Wang C; Li H; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):508-520. PubMed ID: 32370640
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
7. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
8. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
9. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Chari A; Romanus D; Palumbo A; Blazer M; Farrelly E; Raju A; Huang H; Richardson P
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):8-17.e16. PubMed ID: 31722839
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
12. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
[TBL] [Abstract][Full Text] [Related]
13. Utilization of anonymization techniques to create an external control arm for clinical trial data.
Mehtälä J; Ali M; Miettinen T; Partanen L; Laapas K; Niemelä PT; Khorlo I; Ström S; Kurki S; Vapalahti J; Abdelgawwad K; Leinonen JV
BMC Med Res Methodol; 2023 Nov; 23(1):258. PubMed ID: 37925415
[TBL] [Abstract][Full Text] [Related]
14. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
[TBL] [Abstract][Full Text] [Related]
15. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Stewart AK; Jacobus S; Fonseca R; Weiss M; Callander NS; Chanan-Khan AA; Rajkumar SV
Blood; 2015 Sep; 126(11):1294-301. PubMed ID: 26157076
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
[TBL] [Abstract][Full Text] [Related]
17. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
[TBL] [Abstract][Full Text] [Related]
18. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Kuhr K; Wirth D; Srivastava K; Lehmacher W; Hellmich M
Eur J Clin Pharmacol; 2016 Mar; 72(3):257-65. PubMed ID: 26671239
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
